271 related articles for article (PubMed ID: 32982718)
1. Synergistic Effect of Berberine-Based Chinese Medicine Assembled Nanostructures on Diarrhea-Predominant Irritable Bowel Syndrome
Li L; Cui H; Li T; Qi J; Chen H; Gao F; Tian X; Mu Y; He R; Lv S; Chu F; Xu B; Wang P; Lei H; Xu H; Wang C
Front Pharmacol; 2020; 11():1210. PubMed ID: 32982718
[TBL] [Abstract][Full Text] [Related]
2. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats.
Yu ZC; Cen YX; Wu BH; Wei C; Xiong F; Li DF; Liu TT; Luo MH; Guo LL; Li YX; Wang LS; Wang JY; Yao J
World J Gastroenterol; 2019 Aug; 25(29):3956-3971. PubMed ID: 31413530
[TBL] [Abstract][Full Text] [Related]
3. The function of the gut microbiota-bile acid-TGR5 axis in diarrhea-predominant irritable bowel syndrome.
Zhan K; Wu H; Xu Y; Rao K; Zheng H; Qin S; Yang Y; Jia R; Chen W; Huang S
mSystems; 2024 Mar; 9(3):e0129923. PubMed ID: 38329942
[TBL] [Abstract][Full Text] [Related]
4. Effects of Chang-Kang-Fang Formula on the Microbiota-Gut-Brain Axis in Rats With Irritable Bowel Syndrome.
Ling X; Peng S; Zhong J; Guo L; Xu Y; Jin X; Chu F
Front Pharmacol; 2022; 13():778032. PubMed ID: 35614949
[TBL] [Abstract][Full Text] [Related]
5. Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a.
Wei Y; Fan Y; Huang S; Lv J; Zhang Y; Hao Z
Phytomedicine; 2024 Jan; 122():155163. PubMed ID: 37924689
[TBL] [Abstract][Full Text] [Related]
6. The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study.
Wade U; Pascual-Figal DA; Rabbani F; Ernst M; Albert A; Janssens I; Dierckxsens Y; Iqtadar S; Khokhar NA; Kanwal A; Khan A
Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674895
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effectiveness and mechanism of action of the Chang-Kang-Fang formula combined with bifid triple viable capsules on diarrhea-predominant irritable bowel syndrome.
Sun J; Zhang M; Liu W; Liu Y; Zhang D; Fan X; Zhang J; Li T; Lu M
Front Microbiol; 2023; 14():1160783. PubMed ID: 37440881
[TBL] [Abstract][Full Text] [Related]
8. Dose-response effect of berberine on bile acid profile and gut microbiota in mice.
Guo Y; Zhang Y; Huang W; Selwyn FP; Klaassen CD
BMC Complement Altern Med; 2016 Oct; 16(1):394. PubMed ID: 27756364
[TBL] [Abstract][Full Text] [Related]
9. Altered gut microbiota-host bile acid metabolism in IBS-D patients with liver depression and spleen deficiency pattern.
Du L; Zhang Z; Zhai L; Xu S; Yang W; Huang C; Lin C; Zhong LLD; Bian Z; Zhao L
Chin Med; 2023 Jul; 18(1):87. PubMed ID: 37468912
[TBL] [Abstract][Full Text] [Related]
10. Effect of water extract from Berberis heteropoda Schrenk roots on diarrhea-predominant irritable bowel syndrome by adjusting intestinal flora.
Zhu HM; Li L; Li SY; Yan Q; Li F
J Ethnopharmacol; 2019 Jun; 237():182-191. PubMed ID: 30902748
[TBL] [Abstract][Full Text] [Related]
11. Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome.
Mao Q; Shi L; Wang ZG; Luo YH; Wang YY; Li X; Lu M; Ju JM; Xu JD; Kong M; Zhou SS; Shen MQ; Li SL
J Ethnopharmacol; 2017 Apr; 201():123-135. PubMed ID: 28263849
[TBL] [Abstract][Full Text] [Related]
12. Modulation of inflammation by toll-like receptor 4/nuclear factor-kappa B in diarrhea-predominant irritable bowel syndrome.
He X; Cui LH; Wang XH; Yan ZH; Li C; Gong SD; Zheng Y; Luo Z; Wang Y
Oncotarget; 2017 Dec; 8(69):113957-113965. PubMed ID: 29371960
[TBL] [Abstract][Full Text] [Related]
13. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
[TBL] [Abstract][Full Text] [Related]
14. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids.
Yao Y; Chen H; Yan L; Wang W; Wang D
Biomed Pharmacother; 2020 Nov; 131():110669. PubMed ID: 32937246
[TBL] [Abstract][Full Text] [Related]
15. Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome Through Gut Microbiota Modulation.
Li J; Cui H; Cai Y; Lin J; Song X; Zhou Z; Xiong W; Zhou H; Bian Y; Wang L
Front Pharmacol; 2018; 9():1110. PubMed ID: 30323765
[TBL] [Abstract][Full Text] [Related]
16. An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome.
Zhen Z; Xia L; You H; Jingwei Z; Shasha Y; Xinyi W; Wenjing L; Xin Z; Chaomei F
Front Pharmacol; 2021; 12():746923. PubMed ID: 34916934
[TBL] [Abstract][Full Text] [Related]
17. Comparison of five diarrhea-predominant irritable bowel syndrome (IBS-D) rat models in the brain-gut-microbiota axis.
Wu H; Zhan K; Rao K; Zheng H; Qin S; Tang X; Huang S
Biomed Pharmacother; 2022 May; 149():112811. PubMed ID: 35303570
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Effects of Berberine Hydrochloride on Stress-Induced Diarrhea-Predominant Irritable Bowel Syndrome Rats by Inhibiting Neurotransmission in Colonic Smooth Muscle.
Lu Y; Huang J; Zhang Y; Huang Z; Yan W; Zhou T; Wang Z; Liao L; Cao H; Tan B
Front Pharmacol; 2021; 12():596686. PubMed ID: 34594213
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially.
Jia Q; Zhang L; Zhang J; Pei F; Zhu S; Sun Q; Duan L
Biomed Res Int; 2019; 2019():4530203. PubMed ID: 31073525
[TBL] [Abstract][Full Text] [Related]
20. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.
Zhao L; Yang W; Chen Y; Huang F; Lu L; Lin C; Huang T; Ning Z; Zhai L; Zhong LL; Lam W; Yang Z; Zhang X; Cheng C; Han L; Qiu Q; Shang X; Huang R; Xiao H; Ren Z; Chen D; Sun S; El-Nezami H; Cai Z; Lu A; Fang X; Jia W; Bian Z
J Clin Invest; 2020 Jan; 130(1):438-450. PubMed ID: 31815740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
